Search

Your search keyword '"Rodriguez Ortega, Romy"' showing total 9 results
Start Over Author "Rodriguez Ortega, Romy"
9 results on '"Rodriguez Ortega, Romy"'

6. Jerky Movement with Ceftazidime: A Case of Ceftazidime-Induced Neurotoxicity with a Review of the Literature

Author

Al-Sadawi, Mohammed, Rodriguez Ortega, Romy, Sun, Natalie, Abdurahimova, Madina, and McFarlane, Samy I.

Subjects
Article Subject
Abstract

Neurotoxicity manifested as confusion and seizures has been recognized as a side effect of multiple cephalosporins including ceftazidime. Renal impairment and inappropriate dosing are the most common contributors to the development of neurological abnormalities in patients receiving these antibiotics. The presence of baseline neurological abnormalities likely contributes to the frequency of these adverse events. Here, we present a case of a 78-year-old man that developed altered mental status and myoclonic movement after initiation of ceftazidime in the setting of mild renal dysfunction. Resolution of clinical picture was evident after 48 hours of discontinuation of the antibiotic without additional interventions.

Published
2019
Full Text
View/download PDF

9. Novel oral anticoagulants in intracardiac thrombosis resolution: a case series.

Author

Al-Sadawi M, Francois J, Rodriguez Ortega R, Capric V, and Budzikowski AS

Abstract

Background: Vitamin K antagonists (VKAs) have been regarded as the therapy of choice for intracardiac thrombosis for decades based mostly on observational data. The advent of direct oral anticoagulants (DOACs) has displaced VKAs as the first-line therapy for multiple thrombotic disorders but not for intracardiac thrombosis. Although limited, there is growing evidence that DOACs are effective for intracardiac thrombosis and some data suggest that thrombus resolution might be superior to that with warfarin., Case Summary: Here, we present a series of six patients with left atrial appendage thrombi were treated with a venous thromboembolic dose of DOACs with resolution within 2-6 months with no reported complications., Discussion: This case series adds to the accumulating evidence supporting the efficacy of DOACs in the treatment of intracardiac thrombi., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results